[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A MULTICENTER, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND,
PARALLEL-GROUP CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IMMUNE
GLOBULIN INTRAVENOUS (HUMAN) FLEBOGAMMA® 5% DIF IN PATIENTS WITH POST-POLIO
SYNDROME

What is the purpose of the study?

The purpose of this research is to test how well a human immunoglobulin concentrate named Flebogamma® 5% DIF (hereafter referred to as Flebogamma) improves your PPS symptoms such as walking capacity, pain, overall quality of life, fatigue and muscle strength. Flebogamma is the investigational drug. Investigational means that is has not been approved by any health authority (government authorities) such as the US Food and Drug Administration (FDA) and is still being tested for safety and effectiveness.

Upstate Institutional Review Board (IRB) Number:

700301

Study/Protocol ID:

IG1104

Study Phase:

Phase II

Patient Age Group:

Adults

Principal Investigator:

Jenny A Meyer

What is involved if I participate?

  • How long is the study?
    Approx. 18 Months.

Who can I contact for more information?

Name: Marielle N De masi
Phone: 315-464-1670
Email: demasim@upstate.edu

Return to Previous Page || Search Again

Top